Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation.

about

Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation.

Item

http://www.wikidata.org/entity/Q44682134

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Incorporating 18FDG-PET-define ...... ts undergoing chemo-radiation.

@en

Incorporating 18FDG-PET-define ...... ts undergoing chemo-radiation.

@nl

type

Item

label

Incorporating 18FDG-PET-define ...... ts undergoing chemo-radiation.

@en

Incorporating 18FDG-PET-define ...... ts undergoing chemo-radiation.

@nl

prefLabel

Incorporating 18FDG-PET-define ...... ts undergoing chemo-radiation.

@en

Incorporating 18FDG-PET-define ...... ts undergoing chemo-radiation.

@nl

P1476

Incorporating 18FDG-PET-define ...... ts undergoing chemo-radiation.

@en

P2093

Christian Fiandra

http://www.w3.org/2001/XMLSchema#string

Elisabetta Trino

http://www.w3.org/2001/XMLSchema#string

Francesca Arcadipane

http://www.w3.org/2001/XMLSchema#string

Francesca Romana Giglioli

http://www.w3.org/2001/XMLSchema#string

Riccardo Ragona

http://www.w3.org/2001/XMLSchema#string

Umberto Ricardi

http://www.w3.org/2001/XMLSchema#string

P2860

Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective.

Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.

Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.

Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.

A prospective phase II study of magnetic resonance imaging guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy with concurrent chemotherapy for rectal cancer.

Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients

Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.

Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.

Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.

Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.

P2888

s12885-017-3708-4

P304

710

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-017-3708-4

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pierfrancesco Franco

P577

2017-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092508477

http://www.w3.org/2001/XMLSchema#string

P698

29096619

http://www.w3.org/2001/XMLSchema#string

P921

automation

P932

5668955

http://www.w3.org/2001/XMLSchema#string